UK-based Remote Diagnostic Technologies (RTD) has received 510(k) clearance from the US Food and Drug Administration for its Tempus Pro medical monitor.

Tempus Pro will be used as a stand-alone monitor or as a telemedicine system, and is indicated for adults, paediatrics and neonates.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The system is a portable vital signs monitor, which has been developed for use by clinicians and medically qualified personnel for the attended or unattended monitoring of single and multiple vital signs in clinical and pre-hospital care applications.

The approval will allow the system to be used in applications such as 12 Lead ECG recording interpretation, real-time arrhythmia detection, ST and QT monitoring and alarming.

“Tempus Pro, which will be used as a stand-alone monitor or as a telemedicine system, is indicated for adults, paediatrics and neonates.”

Tempus Pro can also be used to determine invasive blood pressure with capabilities of Masimo rainbow SET co-oximetry, video laryngoscope and ultrasound.

The system now offers four channels of invasive pressure, which can be used by critical care users such as CCATT teams.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

RDT Systems Engineering and Test director Dr Leigh Cornock said: “These advances demonstrate RDT’s commitment to ongoing development of the Tempus Pro transport monitor, launched in June last year.

“Expanding the monitor’s capabilities to include video laryngoscopy and ultrasound demonstrate RDT’s proposition of providing users with the ability to leverage more capability from the box they are already carrying.

“As such, we believe Tempus Pro sets a new benchmark in pre-hospital vital signs monitoring and that the bar has been raised yet again.”

Compared with other pre-hospital transport monitors on the market, the system provides all of the Masimo rainbow functions. Addition of all six measurements represents a significant step, providing clinicians with a high level of real time information to help them take informed clinical decisions.

Masimo rainbow extended pulse oximetry allows continuous and immediate measurements of blood constituents and fluid responsiveness non-invasively.

The company’s clearances include: PVI, PI, carboxy haemoglobin (SpCO), metheglobin (SpMet), total haemoglobin (SpHb) and total oxygen content (SpOC). Earlier, the Tempus Pro medical monitor also received CE and other market approvals.